Research Article
MicroRNA181a Is Overexpressed in T-Cell Leukemia/Lymphoma and Related to Chemoresistance
Table 3
Inhibition miR181a expression sensitized T-leukemia/lymphoma cells to chemotherapeutic agents.
|
Agents | IC50 | value | IC50 | value | IC50 | value | IC50 | value | Jurkat control | Jurkat antagomir | Doxorubicin-resistant Jurkat control | Doxorubicin-resistant Jurkat antagomir | H9 control | H9 antagomir | Doxorubicin-resistant H9 control | Doxorubicin-resistant H9 antagomir |
| Cisplatin (uM) | 6.6 ± 0.2 | 5.1 ± 0.1 | 0.0014 | 9.0 ± 0.4 | 7.0 ± 0.4 | 0.0215 | 5.7 ± 0.3 | 4.4 ± 0.2 | 0.0264 | 8.5 ± 0.5 | 6.0 ± 0.5 | 0.0191 | Cyclophosphamide (mM) | 3.3 ± 0.2 | 1.6 ± 0.2 | 0.0018 | 4.8 ± 0.2 | 3.6 ± 0.2 | 0.0214 | 2.4 ± 0.2 | 0.9 ± 0.1 | 0.0019 | 3.9 ± 0.3 | 2.5 ± 0.2 | 0.0134 |
|
|